EXACT Sciences Slumps 5.50% After update on Cologuard tests Print E-mail
By Josh Gee   
Thursday, 25 June 2015 18:22
EXACT Sciences Corporation(NASDAQ:EXAS) has confirmed that it is expecting expects ending quarter two of the year with about 21,000 completed Cologuard tests.
Read more...
 
Evoke Pharma Jumps 20% After Clinical Trial-Phase 2b Assessing EVK-001 Print E-mail
By William Kent   
Wednesday, 24 June 2015 15:00
Speciality pharmaceutical firm Evoke Pharma Inc (NASDAQ:EVOK) has confirmed that the earlier revealed results from the Phase 2b clinical trial assessing EVK-001, the patented formulation of metoclopramide for relief of symptoms related to acute as well as recurrent diabetic gastroparesis in women, has been given in the July issue of the leading peer reviewed journal, Clinical Gastroenterology and Hepatogology.
Read more...
 
Second Sight confirms positive Long-Term Results of the Argus II Retinal Prosthesis System Print E-mail
By William Kent   
Tuesday, 23 June 2015 14:51
Manufacturer of virtual prosthetics, Second Sight Medical Products, which provides useful vision for blind patients, has confirmed three year results post-implant of the Argus II Retinal Prosthesis System from multi-center clinical trial.
Read more...
 
Epizyme Inc. Soars 26% Phase 1 of Tazemetostat Print E-mail
By Marilyn Mullen   
Monday, 22 June 2015 14:03
Biopharmaceutical firm Epizyme Inc. (NASDAQ:EPZM) has come out with results from Phase 1 of Tazemetostat, a first-in-class EZH2 inhibitor, demonstrating decent clinical activity when utilised as oral monotherapy in patients having advanced B-cell non-Hodgkin lymphomas as well as solid tumors.
Read more...
 
Tekmira Slumps 11% After an update on TKM-Ebola-Guinea Print E-mail
By Staff and Wire Reports   
Friday, 19 June 2015 15:26
Industry leading therapeutic solutions firm Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) has confirmed developing cure for hepatitis B virus infection which the Phase II clinical trial of TKM-Ebola-Guinea has achieved.
Read more...
 
Why Radius Health Stock surged Print E-mail
By Marilyn Mullen   
Thursday, 18 June 2015 15:02
Shares of pharmaceutical firm Radius Health, which specialises in making products for treating osteoporosis, surged by over 17% today due to heavy trading after the firm came out with positive clinical data pertaining to investigational drug abaloparatide.
Read more...
 
Avalanche Biotechnologies comes out with positive Top-Line Phase 2a Results for AVA-101 Print E-mail
By William Kent   
Tuesday, 16 June 2015 15:21
Avalanche Biotechnologies has confirmed that the Phase 2a clinical study for AVA-101 has completed objectives of 12-month primary endpoint showing that it was well tolerated having wet age-related macular degeneration.
Read more...
 
AVEO Falls Over 8% After FDA decision on Tivozanib Print E-mail
By Marilyn Mullen   
Friday, 12 June 2015 19:29
AVEO Pharmaceuticals, Inc.(NASDAQ:AVEO) has confirmed receiving written feedback from U.S. Food and Drug Administration for a potential pivotal study for tivozanib in treating NRP-1 low colorectal cancer.  
Read more...
 
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) starts Second Phase 3 Pivotal Study of Epidiolex Print E-mail
By Josh Gee   
Thursday, 11 June 2015 15:00
GW Pharmaceuticals PLC- ADR(NASDAQ:GWPH), which is focussed on developing as well as commercialising novel therapeutics from proprietary cannabinoid product platform has started second of two Phase 3 clinical trials of Epidiolex which treats Lennox-Gastaut syndrome. The LGS is a rare and severe form of childhood-onset epilepsy.
Read more...
 
Vericel Jumps 13% On Plans to Submit Biologics License Application Print E-mail
By Josh Gee   
Wednesday, 10 June 2015 14:55
Vericel Corp. (NASDAQ:VCEL) confirms plans to submit Biologics License Application to FDA by 2015 end for treating Cartilage Defects in the Knee
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 3 of 12

Newsletter